Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 6/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.41 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8624038 | 0.88 | FDFT1 (0.57) | FDFT1FFAR1 | |
| SCHEMBL8622277 | 0.87 | FDFT1 (0.47) | FDFT1LPAR1LPAR5FFAR1MAPK14 | |
| SCHEMBL8625395 | 0.83 | POLB (0.44) | FDFT1 | |
| SCHEMBL8619968 | 0.83 | POLB (0.47) | FDFT1 | |
| SCHEMBL8622242 | 0.82 | LPAR1 (0.39) | FDFT1LPAR1LPAR5PTGS2FFAR1 | |
| SCHEMBL8619955 | 0.81 | FDFT1 (0.53) | FDFT1 | |
| SCHEMBL8618653 | 0.81 | FDFT1 (0.44) | FDFT1 | |
| SCHEMBL8623396 | 0.81 | FFAR1 (0.45) | FDFT1FFAR1 | |
| SCHEMBL8624255 | 0.78 | FDFT1 (0.60) | FDFT1 | |
| SCHEMBL8620506 | 0.78 | S1PR1 (0.50) | FDFT1PTGS2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |